Sangamo Biosciences, Inc. (NASDAQ:SGMO)

CAPS Rating: 2 out of 5

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.

Recs

1
Player Avatar pchop123 (79.73) Submitted: 1/22/2013 1:58:39 PM : Outperform Start Price: $9.50 SGMO Score: -8.86

anticipating positive Phase II results

Featured Broker Partners


Advertisement